Transce3nd’s BioMarin Pharmaceuticals BMRN Stock Holding History

Transce3nd’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7	Closed	-$460	–	1235
2024 Q4	$460	Buy	+7	New	+$469	﹤0.01%	1309

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Transce3nd's BMRN Position: Q1 2025 in Review

Transce3nd sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 7 shares — an estimated $460 sold.

Transce3nd first reported a position in BMRN in Q4 2024 and held it in 1 quarter. The position peaked at $460 in Q4 2024. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Transce3nd reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Transce3nd sold 7 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $460.
Transce3nd first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Transce3nd's BioMarin Pharmaceuticals position peaked at $460 in Q4 2024.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Transce3nd's 13F filing for Q1 2025, filed 5 May 2025.